Nabriva Therapeutics plc
NBRVF · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$0 | -$0 | -$0 | -$0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 31.1% | 441.4% | -35.1% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 19.9% | 51.7% | 68.5% | 99.1% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -153.4% | -174.2% | -1,330.3% | -1,016% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -160.3% | -181.7% | -1,382.2% | -1,068.2% |
| EPS Diluted | -21.32 | -28.52 | -135.23 | -278.75 |
| % Growth | 25.2% | 78.9% | 51.5% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |